陆敏,范韬,周建龙,金骁琦,盛晓东

• 1:扬州大学医学院附属常熟医院心血管内科

摘要(Abstract)：

目的探讨大剂量氯吡格雷维持应用对经皮冠状动脉介入治疗(PCI)术后患者氯吡格雷低反应的发生率及临床事件的影响,并分析发生氯吡格雷低反应的可能相关危险因素。方法选取2014年1月至2015年6月在扬州大学医学院附属常熟医院心血管内科行PCI术的患者134例,应用血栓弹力图(TEG)测定血小板抑制率,根据术后24 h的测定结果分为氯吡格雷低反应组(45例)和氯吡格雷敏感组(89例),术后分别给予氯吡格雷150 mg、每日1次和75 mg、每日1次口服维持,3个月后复查TEG,观察氯吡格雷低反应变化情况并分析氯吡格雷低反应相关危险因素。随访6个月间的主要不良心血管事件(MACE)和出血事件的发生情况。结果 3个月后,氯吡格雷低反应的发生率从33.6%(45/134)降至11.9%(16/134)。随访6个月,两组患者死亡、非致死性心肌梗死的发生率比较,差异均无统计学意义(均P>0.05);氯吡格雷低反应组的总体MACE[15例(33.3%)比20例(22.5%)]、靶血管再次血运重建[5例(11.1%)比6例(6.7%)]、再次因心绞痛住院[12例(26.7%)比15例(16.9%)]的发生率显著高于氯吡格雷敏感组,差异均有统计学意义(均P<0.05)。氯吡格雷低反应的独立影响因素有吸烟史(OR 4.498,95%CI 1.378~4.018,P=0.036)、合并2型糖尿病(OR 4.385,95%CI 1.370~7.552,P=0.026)、氯吡格雷剂量(OR 0.597,95%CI1.005~2.676,P=0.019)。结论对于氯吡格雷低反应的PCI患者,术后3个月持续应用氯吡格雷150 mg、每日1次维持剂量与氯吡格雷敏感患者75 mg、每日1次维持剂量在严重不良事件(包括死亡、非致死性心肌梗死)方面的获益相当。

关键词(KeyWords)： 经皮冠状动脉介入治疗;氯吡格雷低反应;剂量相关

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陆敏,范韬,周建龙,金骁琦,盛晓东

参考文献(References)：

• [1]Müller I,Besta F,Schulz C,et al.Prevalence of clopidogrel nonre-spenders among patients with stable angina pectoris scheduled for elective coronary stent placement.Thromb Haemost,2003,89(5):783-787.
• [2]Angiolillo DJ,Fernandez-Ortiz A,Bernardo E,et al.Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.Diabetes,2005,54(8):2430-2435.
• [3]Gubel PA,Bliden KP,Zaman KA,et al.Clopidogral loading with eptifibatide to arrest the reactivity of platelets:results of clopidogral loading with eptifibatide to arrest the reactivity of platelets(CLEAR PLATEIETS)study.Circulation,2005,111(9):1153-1159.
• [4]Salooga N,Perry DJ.Thrombelastography.Blood Coagul Fibrinolysis,2001,12(5):327-337.
• [5]Tantry US,Bliden KP,Gurbel PA.Overestimation of platelet apirin resistance detection by thrombelagtograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation.J Am Coll Cardiol,2005,46(9):1705-1709.
• [6]No authors listed.An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.N Engl J Med,1993,329(10):673-682.
• [7]龚艳君,屈晨雪,邱林,等.应用血栓弹力图评价经皮冠状动脉介入治疗术后患者抗血小板药物的治疗效果.中国介入心脏病学杂志,2015,23(1):18-21.
• [8]Vadász D,Sztriha LK,Sas K,et al.Aspirin and clopidogrel resistance:possible mechanisms and clinical relevance.PartⅡ:Potential causes and laboratory tests.Ideggyogy Sz,2013,66(1-2):15-22。
• [9]Arya V,Mahajan P,Saraf A,et al.Association of CYP2C19,CYP3A5 and GPⅡb/Ⅲa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.Int J Lab Hematol,2015,37(6):809-818.
• [10]Liu YP,Hao PP,Zhang MX,et al.Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel:An updated meta-analysis.Thomb Res,2011,128(6):593-594.
• [11]Legrand D,Barbato E,Chenu P,et al.The STIB score:a simple clinical test to predict clopidogrel resistance.Acta Cardiol,2015,70(5):516-521.
• [12]Wu ZK,Wang JJ,Wang T,et al.Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome:the role of hyperglycemia and obesity.J Geriatr Cardiol,2015,12(4):378-382.
• [13]Barua RS,Sy F,Srikanth S,et al.Acute cigarette smoke exposure reduces clot-association between altered fibrin arehitceture and the response to t-PA.Thromb Res,2010,126(5):426-430.
• [14]Ferreiro JL,Bhatt DL,Ueno M,et al.Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel:insights from the CAPRIE trial(Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events).J Am Coll Cardiol,2014,63(8):769-777.
• [15]Lundetrom A,Laska AC,Von Arbin M,et al.Glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or TIA.Platelets,2014,25(2):102-110.
• [16]AI-Azzam SI,Alzoubi KH,Khabour OF,et al.Factors that contribute to clopidogrel resistance in cardiovascular disease patients:environmental and genetic approach.Int J Clin Pharmacol Ther,2013,51(3):179-186.
• [17]Wu H,Qian J,Xu J,et al.Effects of CYP2C19 variant alleles on postclopidgrel platelet reactivity and clinical outcomes in an actual clinical setting in China.Pharmacogenet Genomics,2012,22(12):887-890.
• [18]Arya V,Mahajan P,Saraf A,et al.Association of CYP2C19,CYP3A5 and GP IIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.Int J Lab Hematol,2015,37(6):809-818.
• [19]Siller-Matula JM,Huber K,Christ G,et al.Impact of clopidogrel loading dose on clinical outcome in patients under going percutaneous coronary intervention:a systematic review and meta-analysis.Heart,2011,97(2):98-105.
• [20]朱伟军,师军峰,王蕊,等.不同负荷剂量氯吡格雷对急性ST段抬高型心肌梗死患者PCI术后血小板聚集率和超敏C反应蛋白水平的影响.实用临床医药杂志,2015,19(9):129-131.
• [21]Choi H,Ryu J,Seo H,et al.Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients?Int J Clin Pharm,2015,37(5):758-761.
• [22]Tavassoli N,Voisin S,Carrie D,et al.High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.Am J Cardiovasc Drugs,2010,10(1):29-35.
• [23]Metha SR,Bassand JP,Chrolavicius S,et al.Dose comparisons of clopidogrel and asapirin in acute coronary syndromes.N Engl Med,2010,363(10):930-942.
• [24]Liang J,Wang Z,Shi D,et al.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.Angiology,2015,66(4):319-325.
• [25]Gurbel PA,Tantry US.An initial experiment with personalized antiplatelet therapy:the GRAVITAS trial.JAMA,2011,305(11):1136-1137.